Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
40
SNBIF Quote, Financials, Valuation and Earnings
Last price:
$5.81
Seasonality move
:
-2%
Day range:
$5.81 - $5.81
52-week range:
$3.80 - $5.81
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
97.52x
P/B ratio:
102.39x
Volume:
--
Avg. volume:
98
1-year change:
47.09%
Market cap:
$412.1M
Revenue:
--
EPS (TTM):
-$0.28
Analysts' Opinion
-
Consensus RatingSanBio has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, SanBio has an estimated downside of -- from its current price of $5.81.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $5.81.
Fair Value
-
According to the consensus of 0 analysts, SanBio has -- downside to fair value with a price target of -- per share.
SNBIF vs. S&P 500
-
Over the past 5 trading days, SanBio has overperformed the S&P 500 by 2.03% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
SanBio does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
SanBio revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter SanBio reported revenues of --.
Earnings Growth
-
SanBio has grown year-over-year earnings for 0 quarters straight. In the most recent quarter SanBio reported earnings per share of -$0.08.
Enterprise value:
401.8M
EV / Invested capital:
--
Price / LTM sales:
97.52x
EV / EBIT:
--
EV / Revenue:
98.58x
PEG ratio (5yr expected):
-0.09x
EV / Free cash flow:
-4.39x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-10-31 | 2023-10-31 | 2024-10-31 | 2023-10-31 | 2024-10-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$65.3M | -$38M | -$22M | -$4.3M | -$6.2M | |
| EBITDA | -$9.8M | -$50.7M | -$18.5M | $809.8K | -$5.5M | |
| Diluted EPS | -$0.52 | -$0.69 | -$0.28 | -$0.01 | -$0.08 | |
| Period Ending | 2020-10-31 | 2021-10-31 | 2022-10-31 | 2023-10-31 | 2024-10-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $96.8M | $71.2M | $38.3M | $28.1M | $16M | |
| Total Assets | $131M | $72.7M | $38.9M | $28.9M | $16.7M | |
| Current Liabilities | $24.8M | $18.3M | $7.8M | $6.4M | $4.2M | |
| Total Liabilities | $49.9M | $38.5M | $27.6M | $16.3M | $12.7M | |
| Total Equity | $81.2M | $34.2M | $11.3M | $12.6M | $4M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-07-31 | 2023-07-31 | 2024-07-31 | 2023-07-31 | 2024-07-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -$18.9M | -$10.8M | |
| Cash From Investing | -- | -- | -- | -$62.2K | -$23.9K | |
| Cash From Financing | -- | -- | -- | $3.3M | $2.2M | |
| Free Cash Flow | -$111.7M | -$104.9M | -$91.6M | -$18.9M | -$10.9M | |
SNBIF
Sector
Market Cap
$412.1M
$44.6M
Price % of 52-Week High
100%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
47.09%
-29.09%
Beta (5-Year)
-0.336
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$5.81
200-day SMA
Buy
Level
$3.93
Bollinger Bands (100)
Buy
Level
3.48 - 4.54
Chaikin Money Flow
Sell
Level
-2.1K
20-day SMA
Buy
Level
$4.63
Relative Strength Index (RSI14)
Buy
Level
100.00
ADX Line
Neutral
Level
Williams %R
Sell
Level
0
50-day SMA
Buy
Level
$4.16
MACD (12, 26)
Buy
Level
0.54
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Neutral
Level
78.9K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.
Stock Forecast FAQ
In the current month, SNBIF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SNBIF average analyst price target in the past 3 months is --.
-
Where Will SanBio Stock Be In 1 Year?
According to analysts, the consensus estimate is that SanBio share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About SanBio?
Analysts are divided on their view about SanBio share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that SanBio is a Sell and believe this share price will rise from its current level to --.
-
What Is SanBio's Price Target?
The price target for SanBio over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SNBIF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for SanBio is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SNBIF?
You can purchase shares of SanBio via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase SanBio shares.
-
What Is The SanBio Share Price Today?
SanBio was last trading at $5.81 per share. This represents the most recent stock quote for SanBio. Yesterday, SanBio closed at $5.81 per share.
-
How To Buy SanBio Stock Online?
In order to purchase SanBio stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
